experimental investigations suggested that CSCs could be isolated from several types of cancers, including leukaemia [2] [3] [4] and solid tumours. [5] [6] [7] [8] [9] CSCs possess unlimited self-renewal and multilineage differentiation potentials, and played very important roles in tumour initiation, recurrence, metastasis and therapeutic resistance. [10] [11] [12] Due to their properties, CSCs were considered to be responsible for the failure of traditional (surgical operation, radiotherapy and/or chemotherapy) and target therapy as well as tumour relapse. CSCs can be isolated and characterized from tumour tissues and cell lines based on their surface markers (such as, CD133, CD24, CD90, ALDH1, etc.) and Hoechst 33342 exclusion by flow cytometry, and selectively cultured with SFM. [13] [14] [15] CSCs have their own specific surface markers and signalling pathways, which might offer an optimistic opportunity to target eliminating CSCs and/or induce them differentiation for preclinical anti-cancer therapy. However, recent studies indicated that CSCs are not a static cell population with the capacity of initiating tumour through asymmetric cell division, but a cell population in highly dynamic equilibrium state, which could be maintained through the dedifferentiation of matured cancer cells. [16] [17] [18] [19] Until now, the CSC plasticity or dedifferentiation of matured cancer cells (or non-cancer stem cells, non-CSCs) with acquisition of stem-like properties was reported in several cancers. [20] [21] [22] [23] Taken together, all the findings mentioned above suggest that
CSCs and non-CSCs are not in a motionless but in a dynamic equilibrium state: CSCs differentiate into non-CSCs under some circumstances, and non-CSCs could dedifferentiate into CSCs. Therefore,
targeting CSCs seems to be not enough, and blocking the process of non-CSC dedifferentiation to disturb the dynamic equilibrium between CSCs and non-CSCs appears to be particularly important for cancer therapeutics. However, the cellular and molecular mecha- Exosomes, nanovesicles originated from the endosome, are 30-100 nm EVs released by all types of cells. 25 They modulate intercellular communication by transfer their molecular contents between different types of cells. 26 Cancer cell released exosomes that play a crucial role in the intracellular communications involved in cancer progress. 27 These tumour-cell-derived exosomes are found in all body fluids, upon contact with target cells, they can alter phenotypic and functional attributes of recipients, reprogramming them into active contributors to tumour growth, metastasis and immunosuppression. [28] [29] [30] However, the role of exosomes in the reciprocal conversion between non-CSCs and CSCs was rarely investigated. As information carriers between cells, whether exosomes regulate non-CSC dedifferentiation in CSC dynamic equilibrium, and targeting exosome signalling could attenuate the production of CSCs and finally eradicate cancers is worthy of serious study.
| THE CSC PLASTICITY AND TUMOUR

MICROENVIRONMENT
Emerging evidence have been found that non-CSCs could be reprogrammed and transform into CSC-like cells, which indicated that
CSCs and non-CSCs were in a dynamic equilibrium state ( Figure 1A) , and the molecular crosstalk between cancer cells and CSCs in tumour microenvironment seems to play an important role in maintaining of this dynamic equilibrium. Previous studies showed that cancer cells can release and uptake small EVs containing a subset of the membrane and cytosolic proteins, RNA and lipids within the tumour microenvironment, which leads to reprogramming of recipient cells, including stemness phenotype. 44 Thus, it is reasonable to assume that EVs, including exosomes, might mediate the cell communication between non-CSCs and CSCs, and play important roles in maintaining the dynamic equilibrium state of CSCs.
| EXOSOME BIOLOGY
The term "exosome" was first used to describe the exfoliated micro- . 50 During this process, the cytoplasmic DNA, RNA and proteins are specifically sorted into ILVs (pre-exosomes; Figure 2B ). Interestingly, evidence also confirmed that the proportion of proteins and RNAs in exosomes was Moreover, researchers further found that a zip code in the 3 0 -UTR presented in exosomal mRNAs, which may guide their sorting to exosomes. 54 Other studies also found that a specific motif (GGAG) has been involved in the loading of specific miRNAs into exosomes through the interaction with specific chaperone proteins. 55 
| EXOSOME RELEASE
Once formed, these MVBs will be mobilized to the cell periphery, and subsequently fused with the plasma membrane to release the exosomes into extracellular space. 56, 57 In this process, several cellular model systems, including cytoskeleton, Rab GTPase and the fusion machinery, were found to be involved in transporting MVBs to the sites of the plasma membrane and their docking. 58, 59 After docking of two different intracellular compartments, the SNARE complexes drive the fusion of MVBs with the plasma membrane, and finally exosomes were secreted into outer-cellular milieu 50, 60 ( Figure 2C ).
Interestingly, the secretion of exosomal microRNA (miRNA) can be regulated by the neutral sphyngomyelinase 2 (nSMase2), the release of exosomes was reduced after inhibiting the activity of nSMase2
with GW4869, and overexpression of nSMase2 increased extracellular amounts of miRNAs, hypoxia promoted exosomes release along with exosomal miRNA increase, while some drugs could inhibit exosome secretion. [61] [62] [63] These findings indicate that the generation and secretion of exosomes are of modulation and selectivity, and whether this property could be used for cancer therapy needs deeper study.
| EXOSOME UPTAKE
The elicitation of exosomal functions mediating cell-cell communication happened after the uptake by recipient cells. The first step of uptake is the binding of exosomes to the surface of recipient cells, which is mediated by the specific receptors. 64, 65 After initial binding, exosomes will be internalized by recipient cells through endocytic processes, or directly fusion with the cellular membrane and releasing their contents into the cytoplasm and finally regulate cellular pathways 66, 67 ( Figure 2D ). In addition, a recent study showed that treatment of exosomes with proteinase K significantly reduced their uptake by cancer cells. 68 This indicates that the uptake of exosomes by recipient cells might not be a random process, and specific molecules expressed on exosomes may serve as receptors for uptake.
Therefore, blocking the binding between exosomes and recipient cell might be a promising strategy for inhibiting exosome uptake. 86 Challagundla et al 87 found
that neuroblastoma (NBL)-derived exosomes could transfer miR-21 into human monocytes, and then up-regulate miR-155 levels to enhance NBL drug resistance. Moreover, certain stemness and metastasis-related mRNA were found to be enriched in breast cancer stem-like cell-derived exosomes that could stimulate tumour progression. 88 Besides, several studies demonstrated that long non-coding RNA Fortunately, recent studies revealed the possible mechanisms involved in the exosome biogenesis, release and uptake; thus, many potential strategies to interrupt exosome-mediated signalling can be envisioned (Figure 2 
| EXOSOME S AS D RUG-D ELIVERY VEHICLES FOR TARGETED CANCER THE RAPY
Unlike synthetic nanoparticles, the lipid bilayer membrane of exosomes can pass through the blood-brain barrier and have low toxicity and immunogenicity. 105 Anti-inflammatory or chemotherapeutic drugs delivered by exosomes exhibited much stronger stability, bioavailability and effectiveness, and no toxicity compared with conventional therapy. 106 Therefore, developing more specific CSC targeting exosomes will be a promising cancer therapy strategy in the future.
| CONCLUDING REMARKS
Originally, CSCs were thought to be a fixed subset of cancer cells 
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